Noninvasive and minimally invasive techniques for the diagnosis and management of allergic diseases

Baumann, Ralf; Untersmayr, Eva; Zissler, Ulrich M.; Eyerich, Stefanie; Adcock, Ian M.; Brockow, Knut; Biedermann, Tilo; Ollert, Markus; Chaker, Adam; Pfaar, Oliver; Garn, Holger; Thwaites, Ryan S.; Togias, Alkis; Kowalski, Marek L.; Hansel, Trevor T.; Jakwerth, Constanze A.; Schmidt‐Weber, Carsten B.

doi:10.1111/all.14645

Cited by 23 publications

(23 citation statements)

References 140 publications

(244 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The members of the SCGB family are easily accessible, chemically stable, and abundant in several biomatrices (serum, BALF, nasopharyngeal fluids, urine, exhaled breath condensate 69 ). Since they can be detected in many secretory tissues, they have a high potential as biomarkers for diagnostic and prognostic assessment as well as for therapy monitoring.…”

Section: Current Status Of Secretoglobins As Biomarkersmentioning

confidence: 99%

Secretoglobins in the big picture of immunoregulation in airway diseases

Mootz

Jakwerth

Schmidt‐Weber

et al. 2021

Allergy

Self Cite

View full text Add to dashboard Cite

The proteins of the secretoglobin (SCGB) family are expressed by secretory tissues of barrier organs. They are embedded in immunoregulatory and anti‐inflammatory processes of airway diseases. This review particularly illustrates the immune regulation of SCGBs by cytokines and their implication in the pathophysiology of airway diseases. The biology of SCGBs is a complex topic of increasing importance, as they are highly abundant in the respiratory tract and can also be detected in malignant tissues and as elements of immune control. In addition, SCGBs react to cytokines, they are embedded in Th1 and Th2 immune responses, and they are expressed in a manner dependent on cell maturation. The big picture of the SCGB family identifies these factors as critical elements of innate immune control at the epithelial barriers and highlights their potential for diagnostic assessment of epithelial activity. Some members of the SCGB family have so far only been superficially examined, but have high potential for translational research.

show abstract

Section: Current Status Of Secretoglobins As Biomarkersmentioning

confidence: 99%

Secretoglobins in the big picture of immunoregulation in airway diseases

Mootz

Jakwerth

Schmidt‐Weber

et al. 2021

Allergy

Self Cite

View full text Add to dashboard Cite

show abstract

“…This concept postulates that the upper and lower airways form a morphological and functional unit, sharing common features related to physical barrier, mucociliary clearance and immune processes. These mechanisms can be studied in the lower airways using induced sputum samples, which consists of components derived from the respiratory epithelium of the central airways 10–12 …”

Section: Introductionmentioning

confidence: 99%

“…These mechanisms can be studied in the lower airways using induced sputum samples, which consists of components derived from the respiratory epithelium of the central airways. [10][11][12] MicroRNAs (miRs) are small nucleic acid molecules that suppress gene expression post-transcriptionally and therefore via an epigenetic mechanism. 13 Individual miRs can have wide-ranging regulatory functions, as they can each target multiple mRNA transcripts along a particular signalling pathway.…”

Section: Introductionmentioning

confidence: 99%

Sputum microRNA‐screening reveals Prostaglandin EP3 receptor as selective target in allergen‐specific immunotherapy

Jakwerth

Chaker

Guerth

et al. 2021

Clin Experimental Allergy

Self Cite

View full text Add to dashboard Cite

Background Several microRNAs (miRs) have been described as potential biomarkers in liquid biopsies and in the context of allergic asthma, while therapeutic effects on the airway expression of miRs remain elusive. In this study, we investigated epigenetic miR‐associated mechanisms in the sputum of grass pollen‐allergic patients with and without allergen‐specific immunotherapy (AIT). Methods Induced sputum samples of healthy controls (HC), AIT‐treated and ‐untreated grass pollen‐allergic rhinitis patients with (AA) and without asthma (AR) were profiled using miR microarray and whole‐transcriptome microarray analysis of the same samples. miR targets were predicted in silico and used to identify inverse regulation. Local PGE2 levels were measured using ELISA. Results Two hundred and fifty nine miRs were upregulated in the sputum of AA patients compared with HC, while only one was downregulated. The inverse picture was observed in induced sputum of AIT‐treated patients: while 21 miRs were downregulated, only 4 miRs were upregulated in asthmatics upon AIT. Of these 4 miRs, miR‐3935 stood out, as its predicted target PTGER3, the prostaglandin EP3 receptor, was downregulated in treated AA patients compared with untreated. The levels of its ligand PGE2 in the sputum supernatants of these samples were increased in allergic patients, especially asthmatics, and downregulated after AIT. Finally, local PGE2 levels correlated with ILC2 frequencies, secreted sputum IL‐13 levels, inflammatory cell load, sputum eosinophils and symptom burden. Conclusions While profiling the sputum of allergic patients for novel miR expression patterns, we uncovered an association between miR‐3935 and its predicted target gene, the prostaglandin E3 receptor, which might mediate AIT effects through suppression of the PGE2‐PTGER3 axis.

show abstract

“…112 Thorough endotyping of AE patients would be very efficient and cost-effective for treatment. 113 One possible method would be tape stripping, which successfully revealed multiple AE markers in a current study. 114 Biomarkers are essential for diagnosis and personalized and tailored therapy, especially in a multifaceted disease as AE.…”

Section: B I Omark Er S For D Is E a S E S E Verit Ymentioning

confidence: 81%

A new era of atopic eczema research: Advances and highlights

Hülpüsch

Weins

Traidl‐Hoffmann

et al. 2021

Allergy

View full text Add to dashboard Cite

Atopic eczema (AE) or atopic dermatitis (AD) is an inflammatory skin disease with involvement of genetic, immunological and environmental factors which are highly interconnected. 1,2 The heterogenic disease can be separated into different phenotypes and clinical presentations defined by the ethnicity, disease onset, disease severity, chronic vs acute, intrinsic vs extrinsic (IgE level), paediatric vs adult and inflammatory signature. [3][4][5] A common feature of all subtypes is a tremendous psychosocial burden for all patients with AE. 6 Prevalence varies by area and is reported to be 15-20% in children in Europe, persisting in up to 5-10% of adults. [7][8][9] Although severe cases are less abundant than mild or moderate disease pattern, 2% of affected children are severely suffering. 7,9 Therefore, AE remains to be a high and even increasing socio-economic burden in the United States and in Europe, 10,11 whereas slightly decreasing numbers were reported over the last few years in Japan. 12 Children often overcome atopic eczema, but set off on the so-called 'atopic march', that is begin a classic 'allergy career'. Scientifically, AE is a risk factor for the development of allergies. These are primarily type I allergies with clinical features such as hay fever and asthma. Allergies are increasingly becoming a widespread disease. Currently, almost every fourth person in Europe suffers from symptoms such as asthma or hay fever and the associated restrictions in everyday life or at work. For society, the reduced ability to perform at school, university and at work means great socio-economic damage.

show abstract

Noninvasive and minimally invasive techniques for the diagnosis and management of allergic diseases

Cited by 23 publications

References 140 publications

Secretoglobins in the big picture of immunoregulation in airway diseases

Secretoglobins in the big picture of immunoregulation in airway diseases

Sputum microRNA‐screening reveals Prostaglandin EP3 receptor as selective target in allergen‐specific immunotherapy

A new era of atopic eczema research: Advances and highlights

Contact Info

Product

Resources

About